VIRIDIAN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.88 USD | +1.42% |
|
-11.78% | -40.86% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15.26 | 64.29 | 429.5 | 1,176 | 1,145 | 822 | - | - |
| Enterprise Value (EV) 1 | -7.262 | 64.29 | 232.5 | 755.7 | 688.2 | 403.8 | 234.9 | 392 |
| P/E ratio | -0.36 x | -0.53 x | -2.96 x | -7.21 x | -4.1 x | -2.93 x | -2.96 x | -4.84 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.42 x | 61.2 x | 145 x | 663 x | 3,648 x | 2,678 x | 265 x | 5.01 x |
| EV / Revenue | -1.63 x | 61.2 x | 78.5 x | 426 x | 2,192 x | 1,315 x | 75.6 x | 2.39 x |
| EV / EBITDA | - | - | -3.57 x | -5.64 x | -3.68 x | -2.76 x | -1.34 x | -2.11 x |
| EV / FCF | - | -2,155,836 x | -4,259,465 x | -7,985,907 x | - | - | - | - |
| FCF Yield | - | -0% | -0% | -0% | - | - | - | - |
| Price to Book | - | - | - | 3.05 x | - | - | - | - |
| Nbr of stocks (in thousands) | 2,119 | 3,908 | 21,722 | 40,248 | 52,586 | 63,822 | - | - |
| Reference price 2 | 7.199 | 16.45 | 19.77 | 29.21 | 21.78 | 12.88 | 12.88 | 12.88 |
| Announcement Date | 20-03-11 | 21-03-26 | 22-03-10 | 23-03-08 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.461 | 1.05 | 2.963 | 1.772 | 0.314 | 0.307 | 3.106 | 163.9 |
| EBITDA 1 | - | - | -65.14 | -134 | -186.8 | -146.5 | -175.9 | -186.1 |
| EBIT 1 | -41.98 | -110.4 | -79.73 | -134.3 | -254.4 | -283.4 | -310.9 | -190.1 |
| Operating Margin | -941.02% | -10,512.38% | -2,690.79% | -7,579.23% | -81,035.03% | -92,303.19% | -10,009.68% | -115.94% |
| Earnings before Tax (EBT) 1 | -41.87 | -110.7 | -79.41 | -129.9 | -237.7 | -259.9 | -282.6 | -139.4 |
| Net income 1 | -41.87 | -110.7 | -79.41 | -129.9 | -237.7 | -266.4 | -292.9 | -182.9 |
| Net margin | -938.65% | -10,544.29% | -2,680.16% | -7,329.23% | -75,711.46% | -86,774.35% | -9,431.04% | -111.6% |
| EPS 2 | -20.10 | -31.13 | -6.680 | -4.050 | -5.310 | -4.396 | -4.346 | -2.662 |
| Free Cash Flow | - | -29.82 | -54.58 | -94.64 | - | - | - | - |
| FCF margin | - | -2,840.1% | -1,842.09% | -5,340.58% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-03-11 | 21-03-26 | 22-03-10 | 23-03-08 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.208 | 0.214 | 0.216 | 0.256 | 1.195 | 0.105 | 0.098 | 0.072 | 0.072 | 0.072 | 0.1215 | 0.1236 | 0.1216 | 0.1237 | 0.036 |
| EBITDA 1 | -10.12 | -25.56 | -21.19 | -24.62 | -24.84 | -48.97 | -57.15 | -46.84 | -51.09 | -45.28 | -33.64 | -35.34 | -37.43 | -40.13 | - |
| EBIT 1 | -14.13 | -29.08 | -25.89 | -29.56 | -29.78 | -49.07 | -72.47 | -59.28 | -51.22 | -71.48 | -67 | -70.07 | -71.66 | -74.82 | -71.25 |
| Operating Margin | -6,795.19% | -13,589.25% | -11,985.65% | -11,548.44% | -2,492.47% | -46,729.52% | -73,952.04% | -82,326.39% | -71,144.44% | -99,276.39% | -55,147.24% | -56,703.75% | -58,939.63% | -60,502.63% | -197,927.78% |
| Earnings before Tax (EBT) 1 | -14.04 | -28.95 | -25.69 | -29.49 | -28.9 | -45.78 | -68.15 | -55.06 | -47.66 | -66.86 | -61.14 | -64.3 | -65.58 | -68.94 | -66.55 |
| Net income 1 | -14.04 | -28.95 | -25.69 | -29.49 | -28.9 | -45.78 | -68.15 | -55.06 | -47.66 | -66.86 | -62.47 | -65.31 | -68.24 | -70.04 | -66.55 |
| Net margin | -6,751.44% | -13,526.17% | -11,894.91% | -11,519.92% | -2,418.83% | -43,604.76% | -69,541.84% | -76,476.39% | -66,194.44% | -92,861.11% | -51,417.65% | -52,844.97% | -56,124.36% | -56,632.31% | -184,873.61% |
| EPS 2 | -1.250 | -1.320 | -0.9800 | -1.060 | -0.8600 | -1.130 | -1.610 | -1.270 | -1.090 | -1.350 | -1.071 | -1.077 | -1.096 | -1.107 | -0.9400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-05 | 22-03-10 | 22-05-12 | 22-08-15 | 22-11-14 | 23-03-08 | 23-05-10 | 23-08-08 | 23-11-13 | 24-02-27 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 22.5 | - | 197 | 420 | 457 | 418 | 587 | 430 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -29.8 | -54.6 | -94.6 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | 9.560 | - | - | - | - |
| Cash Flow per Share | - | - | - | -2.920 | - | - | - | - |
| Capex 1 | - | 0.04 | - | 0.8 | 0.9 | 1 | 1 | 1 |
| Capex / Sales | - | 4% | - | 44.98% | 285.99% | 325.73% | 32.2% | 0.61% |
| Announcement Date | 20-03-11 | 21-03-26 | 22-03-10 | 23-03-08 | 24-02-27 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
12.88
USD
Average target price
39.36
USD
Spread / Average Target
+205.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.86% | 822M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- VRDN Stock
- Financials Viridian Therapeutics, Inc.
